Results 201 to 210 of about 303,324 (255)

Pre‐Encoded IFN‐I Sensitivity Exacerbates Memory T Cell Senescence in Solid Tumors

Advanced Science, EarlyView.
Type I interferon (IFN‐I) signaling promotes p21‐dependent cell cycle arrest in senescent tumor‐specific memory T cells, resulting in poor proliferative responses and solid tumor regression during cancer vaccination. Conversely, IFNα/β receptor blockade reinvigorates T cell proliferation to regress solid tumors and is more effective with increasing ...
Andrew Nguyen, Scott R Walsh, Li Deng, Lan Chen, Yonghong Wan   +4 more
wiley   +1 more source

Circulating tumor cells (CTCs) enumeration and machine-learning based diagnostic biomarkers for breast cancer detection. [PDF]

BMC Cancer
Liu CY, Lin YH, Tsai YF, Lu PY, Chen JL, Li YH, Huang CC, Lin YS, Chao TC, Feng CJ, Hsu CY, Chiu JH, Chen CM, Tseng LM.   +13 more
europepmc   +1 more source

Tailoring Vascular‐Immune Homeostasis via Manganese‐DNA Complex‐Armed Immunogenic Extracellular Vesicles for Pancreatic Cancer Immunotherapy

Advanced Science, EarlyView.
This study demonstrates that Mn2⁺–tumor DNA complexes encapsulated in dendritic cell (DC)– derived immunogenic extracellular vesicles (EVDC@Mn‐DNA) act as a DC‐specific cGAS– STING activator. EVDC@Mn‐DNA treatment enhances intratumoral DC activation, improves tumor vascular function, promotes CD8⁺ T cell activity, and suppresses pancreatic tumor growth,
Xue Jiang, Lihuan Shang, Xiaochun Chen, Xiangzhan Kong, Xiaojuan Wang, Linjia Jiang, Huiying Zhao, Yafeng Zhu, Cheng Huang, Shiyi Deng, Rui Zhang, Minghui Wang, Haoming Lin, Ping‐Pui Wong   +13 more
wiley   +1 more source

Circulating Tumor Cells in Uveal Melanoma: Multi-Marker Detection and Association With Disease State. [PDF]

Invest Ophthalmol Vis Sci
de Bruyn DP, Bassil FL, Wu M, Beasley AB, Vaarwater J, Van MN, Kraan J, Verdijk RM, Paridaens D, van Rij CM, Naus NC, de Klein A, Gray ES, Brosens E, Kiliç E.   +14 more
europepmc   +1 more source

Mesenchymal Stromal Cell‐Mediated Intercellular Communication: Mapping the Interactome for Skeletal Muscle Homeostasis and Regeneration

Advanced Science, EarlyView.
Liu et al. define a systems‐level interactome of fibroadipogenic progenitor (FAP)‐mediated signaling in skeletal muscle by integrating single‐cell transcriptomics with FAP depletion‐based perturbation analysis. Functional interrogation using a conditioned media bioassay links predicted signaling to multicellular outcomes, establishing a framework to ...
Xingyu Liu, Edgar E. Perez Carbajal, Yih‐Chii Hwang, Sahil A. Mapkar, Benjamin W. Gilman, Sarah A. Bliss, Lam B. Tran, Kalgi T. Mehta, Jacob O. Banyasz, Ming Yu, Reynold R. Liu, Matthew N. Ly, Christapher S. Morrissey, Michael N. Wosczyna   +13 more
wiley   +1 more source

Circulating tumor cells: indicators of cancer progression, plasticity and utility for therapies. [PDF]

Pathol Oncol Res
Linkner TR, Nagy ZB, Kalmár A, Farkas E, Bányai F, Szakállas N, Takács I, Molnár B.   +7 more
europepmc   +1 more source

PD‐1 Inhibits CD4+ TRM‐Mediated cDC1 Mobilization via Suppressing JAML in Human NSCLC

Advanced Science, EarlyView.
CD4+ tissue‐resident memory T cells (TRMs) in non‐small cell lung cancer recruit conventional type 1 dendritic cells via XCL1‐XCR1 signaling, orchestrating antitumor immunity. The costimulatory molecule JAML is essential for this process. PD‐1 blockade restores JAML expression and cDC1 mobilization, while JAML agonists synergize with anti‐PD‐1 therapy,
Zheyu Shao, Qinyuan Liu, Zhongwei Xin, Zhiyao Zhou, Mingjie Lin, Di Chen, Zhixing Hao, Yongyuan Chen, Wenxuan Wu, Shuyang Zhang, Xiaoke Chen, Xia Xu, Jinfan Li, Wei Lin, Yuhao Lu, Dang Wu, Pin Wu   +16 more
wiley   +1 more source

Circulating Tumor Cells and Cancer Stem Cells: Clinical Implications in Nonmetastatic Breast Cancer

Breast Cancer: Basic and Clinical Research, 2016
M. Sayed, A.M. Zahran, M.S.F. Hassan, D.O. Mohamed   +3 more
doaj  

Clinical applications of circulating tumor cells in metastasis and therapy. [PDF]

J Hematol Oncol
Yang C, Liu C, Xia C, Fu L.
europepmc   +1 more source

Anti‐PD‐1 Nanobody‐Armored MSLN CAR‐T Therapy for Malignant Mesothelioma: Preclinical and Clinical Studies

Advanced Science, EarlyView.
A novel therapy using engineered immune cells (NAC‐T cells) showed promise for refractory malignant mesothelioma. Based on the encouraging preclinical data, the first‐in‐human trial is initiated, demonstrating tolerable safety and promising anti‐tumor activity (ORR 63.6%, DCR 100%, including one CR).
Yan Sun, Haochen Yang, Qing Xu, Xingya Li, Jinxing Lou, Jianchun Duan, Jiachen Xu, Zhuqing Liu, Yong Xia, Zhicai Lin, Linlin Li, Dan Sun, Jiaguo Li, Tao Liu, Jun Guo, Wenfeng Xu, Weimin Zhu, Yi Liu, Boyang Sun, Jia Zhong, Lijie Rong, Qijun Qian, Chenqi Xu, Jie Wang   +23 more
wiley   +1 more source